Results 91 to 100 of about 260,030 (390)

The KRASG12C Inhibitor, MRTX849, Provides Insight Toward Therapeutic Susceptibility of KRAS Mutant Cancers in Mouse Models and Patients.

Cancer Discovery, 2019
Despite decades of research, efforts to directly target KRAS have been challenging. MRTX849 was identified as a potent, selective, and covalent KRASG12C inhibitor that exhibits favorable drug-like properties, selectively modifies mutant cysteine 12 in ...
J. Christensen, Jill Hallin, Lars D. Engstrom, Lauren N. Hargis, Andrew Calinisan, Ruth Aranda, David M Briere, Niranjan Sudhakar, Vickie Bowcut, B. R. Baer, J. Ballard, M. Burkard, Jay B. Fell, J. Fischer, G. Vigers, Jenny Y. Xue, Sole Gatto, J. Fernandez-Banet, A. Pavlícek, K. Velastegui, R. Chao, J. Barton, M. Pierobon, E. Baldelli, Emmanuel F Patricoin, Douglas P Cassidy, M. Marx, I. Rybkin, M. Johnson, S. Ou, P. Lito, K. Papadopoulos, P. Janne, P. Olson   +33 more
semanticscholar   +1 more source

Cetuximab promotes RSL3-induced ferroptosis by suppressing the Nrf2/HO-1 signalling pathway in KRAS mutant colorectal cancer

Cell Death and Disease, 2021
Cetuximab is approved for the treatment of metastatic colorectal cancer (mCRC) with RAS wild-type. Nevertheless, the prognosis remains poor and the effectiveness of cetuximab is limited in KRAS mutant mCRC.
Jiawen Yang, Jiajie Mo, Juji Dai, Chen-Yang Ye, Weiya Cen, Xuzhi Zheng, Lei Jiang, L. Ye   +7 more
semanticscholar   +1 more source

KRAS Binders Hidden in Nature [PDF]

Chemistry – A European Journal, 2019
AbstractInvited for the cover of this issue is the group of Darryl McConnell and colleagues from Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria. The image depicts some of the KRAS binders found in Nature that are discussed in the paper. Read the full text of the article at 10.1002/chem.201902810.
Andreas Mantoulidis, Dirk Kessler, Moriz Mayer, Darryl B. McConnell, Laetitia J. Martin, Laetitia J. Martin, Andreas Bergner, Gabriella Siszler, Wolfgang Hela, Xiao-Ling Cockcroft, Gerhard Fischer, Roland Kousek, Barbara Müllauer, Bernhard Wolkerstorfer, Andreas Gollner   +14 more
openaire   +3 more sources

EGFR‐STAT3 activation provides a therapeutic rationale for targeting aggressive ETV1‐positive prostate cancer

Molecular Oncology, EarlyView.
Cotargeting EGFR and STAT3 with Erlotinib and TTI‐101 impairs both 2D and 3D growth of ETV1‐overexpressing prostate cancer cells by disrupting a self‐sustaining ETV1–EGFR positive feedback loop that promotes EGFR and STAT3 expression and phosphorylation (activation).
Elsa Gomes Paiva, Bernardo Orr, Ana Azeredo, Andreia Brandão, Manuel R. Teixeira, Paula Paulo   +5 more
wiley   +1 more source

Direct Targeting KRAS Mutation in Non-Small Cell Lung Cancer: Focus on Resistance

Cancers, 2022
Simple Summary KRAS is the most frequently mutated oncogene in non-small cell lung cancers (NSCLC), with a frequency around 30%, and among them KRAS G12C mutation occurs in 11% of cases. KRAS mutations were for a long time considered to be non-targetable
Damien Reita, L. Pabst, E. Pencreach, E. Guérin, L. Dano, V. Rimelen, Anna Voegeli, L. Vallat, C. Mascaux, M. Beau-Faller   +9 more
semanticscholar   +1 more source

Transient disappearance of RAS mutant clones in plasma: A counterintuitive clinical use of EGFR inhibitors in RAS mutant metastatic colorectal cancer [PDF]

, 2019
Genomic studies performed through liquid biopsies widely elucidated the evolutionary trajectory of RAS mutant clones under the selective pressure of EGFR inhibitors in patients with wild type RAS primary colorectal tumors. Similarly, the disappearance of
Belardinilli, Francesca, Cortesi, Enrico, Gazzaniga, Paola, Gelibter, ALAIN JONATHAN, Giannini, Giuseppe, Gradilone, Angela, Loreni, Flavia, Mahdavia, Yasaman, Nicolazzo, Chiara, Raimondi, Cristina   +9 more
core   +1 more source

Unveiling unique protein and phosphorylation signatures in lung adenocarcinomas with and without ALK, EGFR, and KRAS genetic alterations

Molecular Oncology, EarlyView.
Proteomic and phosphoproteomic analyses were performed on lung adenocarcinoma (LUAD) tumors with EGFR, KRAS, or EML4–ALK alterations and wild‐type cases. Distinct protein expression and phosphorylation patterns were identified, especially in EGFR‐mutated tumors. Key altered pathways included vesicle transport and RNA splicing.
Fanni Bugyi, Mirjam Balbisi, Simon Sugár, Lóránd Váncza, Eszter Regős, Ilona Kovalszky, Ibolya Laczó, Tünde Harkó, Gábor Kecskeméti, Zoltán Szabó, Judit Moldvay, László Drahos, Lilla Turiák   +12 more
wiley   +1 more source

Razumevanje okoljskih problemov na dinarskem krasu

Dela, 2003
Na glavnih območjih dinarskega krasa, na Krasu, jadranskih otokih in nizkih ravnikih ob dalmatinski obali prevladujeta tipično sredozemska raba tal, ki povzroča tudi spreminjanje površja, npr.
Jean Nicod
doaj   +1 more source

Gradišča Komenskega Krasa v starejši železni dobi

Arheološki Vestnik, 2021
Prispevek prinaša nova spoznanja o poselitvi Komenskega Krasa v starejši železni dobi. Podrobneje so obravnavana tri v arheološki literaturi že znana najdišča, to so Tomaj, Štanjel in Zagrajec, kjer so bile v zadnjih desetletjih izvedene arheološke ...
Patricija BRATINA
doaj   +1 more source

A pan-KRAS degrader for the treatment of KRAS-mutant cancers

Cell Discovery
AbstractKRAS mutations are highly prevalent in a wide range of lethal cancers, and these mutant forms of KRAS play a crucial role in driving cancer progression and conferring resistance to treatment. While there have been advancements in the development of small molecules to target specific KRAS mutants, the presence of undruggable mutants and the ...
Jie Yang, Qiao-Li Wang, Guan-Nan Wang, Jia-Cong Ye, Zi-Qian Li, Jing-Yun Wang, Zhao-Hui Liang, Shu-Xin Li, Cong Sun, Wen-Ting Liao, Yi-Jun Gao, Jing Wang, Yong Mao, Chunjing Yu, Guo-Kai Feng, Mu-Sheng Zeng   +15 more
openaire   +3 more sources